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We have previously shown that the adenosine analog 5-aminoimidazole-4-carboxamide-1-h-d-ribofuranoside (AICAR), an activator of
AMP-activated protein kinase (AMPK), stimulates an increase in AMPK activity and induces meiotic resumption in mouse oocytes [Downs,
S.M., Hudson, E.R., Hardie, D.G., 2002. A potential role for AMP-activated protein kinase in meiotic induction in mouse oocytes. Dev. Biol,
245, 200–212.]. The present study was carried out to better define a causative role for AMPK in oocyte meiotic maturation. When
microinjected with a constitutively active AMPK, about 20% of mouse oocytes maintained in meiotic arrest with dibutyryl cAMP (dbcAMP)
were stimulated to undergo germinal vesicle breakdown (GVB), while there was no effect of catalytically dead kinase. Western blot analysis
revealed that germinal vesicle (GV)-stage oocytes cultured in dbcAMP-containing medium plus AICAR possessed elevated levels of active
AMPK, and this was confirmed by AMPK assays using a peptide substrate of AMPK to directly measure AMPK activity. AICAR-induced
meiotic resumption and AMPK activation were blocked by compound C or adenine 9-beta-d-arabinofuranoside (araA, a precursor of araATP),
both inhibitors of AMPK. Compound C failed to suppress adenosine uptake and phosphorylation, indicating that it did not block AICAR
action by preventing its metabolism to the AMP analog, ZMP. 2V-Deoxycoformycin (DCF), a potent adenosine deaminase inhibitor, reversed
the inhibitory effect of adenosine on oocyte maturation by modulating intracellular AMP levels and activating AMPK. Rosiglitazone, an anti-
diabetic agent, stimulated AMPK activation in oocytes and triggered meiotic resumption. In spontaneously maturing oocytes, GVB was
preceded by AMPK activation and blocked by compound C. Collectively, these results support the proposition that active AMPK within mouse
oocytes provides a potent meiosis-inducing signal in vitro.
D 2005 Elsevier Inc. All rights reserved.Keywords: Mouse oocytes; AMP-activated protein kinase; Meiotic resumption; Compound CIntroduction
Mammalian oocytes are arrested in the diplotene stage of the
first meiotic prophase soon after initiating meiosis. The
meiotically arrested oocyte is characterized by a prominent
nucleus, termed the germinal vesicle (GV), which is main-
tained throughout the period of oocyte growth. Fully grown
oocytes within healthy, non-atretic secondary follicles are
triggered to resume meiotic maturation in response to a
preovulatory gonadotropin surge. This process is manifested
by germinal vesicle breakdown (GVB), a morphological
change commonly used to monitor meiosis initiation.0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2005.11.039
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E-mail address: Stephen.Downs@Marquette.edu (S.M. Downs).The mechanism by which oocytes overcome the prophase I
meiotic arrest is not well understood. Oocytes cultured within
their follicles in vitro are maintained in meiotic arrest unless
stimulated by gonadotropin. When the oocyte is removed from
the intrafollicular environment and cultured under permissible
conditions, maturation occurs spontaneously in the absence of
hormone stimulation, indicating a dependence on the follicular
somatic compartment for maintenance of prophase I arrest. If
cumulus cell-enclosed oocytes are isolated from follicles and
maintained at the GV stage in vitro with exogenous inhibitor,
meiotic resumption can be elicited by gonadotropin. This
phenomenon is mediated by the cumulus cells that produce a
signal driving the oocyte into meiotic maturation.
Cyclic adenosine monophosphate (cAMP) plays an impor-
tant role in the regulation of meiotic resumption in oocytes.91 (2006) 227 – 238
www.e
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that prevent degradation of intracellular cAMP reversibly
suppress oocyte maturation. cAMP prevents GVB through the
activation of cAMP-dependent protein kinase (PKA). Indeed,
mouse oocytes maintained in meiotic arrest by elevated
cAMP can be induced to resume maturation by microinjection
of PKA inhibitors (Bornslaeger et al., 1986; Eppig, 1989). In
Xenopus oocytes, PKA phosphorylates and inactivates cdc25
phosphatase, thereby blocking activation of maturation
promoting factor (cdc2 kinase) and contributing to meiotic
arrest (Duckworth et al., 2002). Recently, protein tyrosine
phosphatase nonreceptor type 13 (PTPN13), a substrate of
PKA in both mouse and Xenopus oocytes, has been
implicated in the regulation of oocyte meiotic resumption
(Nedachi and Conti, 2004).
Oocyte cAMP synthesis and hydrolysis are regulated via
adenylyl cyclase and cyclic nucleotide phosphodiesterase
(PDE), respectively. PDE3A is the predominant PDE isoform
expressed in rodent oocytes (Shitsukawa et al., 2001; Conti et
al., 2002), and its activity is increased prior to oocyte
maturation (Richard et al., 2001). PDE3A-null female mice
are infertile as oocytes are ovulated in the immature GV stage
(Masciarelli et al., 2004). PDE3A-null oocytes lack cAMP-
specific PDE activity, contain increased cAMP levels, are
persistently maintained in the GV stage in vivo and failed to
undergo spontaneous maturation in vitro. These data indicate
that PDE activity is required for oocyte maturation.
The product of PDE activity and cAMP degradation, 5V-
AMP, is a potent stimulator of the stress response kinase,
AMP-activated protein kinase (AMPK), and has been sug-
gested to have an important meiosis induction function via
activating AMPK (Downs et al., 2002). AMPK, a serine/
threonine kinase, composed of an a catalytic subunit and h and
g regulatory subunits, is a pivotal enzyme in the regulation of
cellular energy charge (Hardie and Hawley, 2001; Hardie,
2004; Kahn et al., 2005). AMPK is activated by an upstream
kinase, recently identified as the tumor repressor, LKB1
(Hawley et al., 2003; Woods et al., 2003), via phosphorylation
of Thr-172 on the a subunit (Hawley et al., 1996). Binding of
AMP or ATP to CBS domains on the g subunit (Scott et al.,
2004) regulates the activation state of the kinase (reviewed by
Hardie and Hawley, 2001; Hardie, 2004). AMP promotes
phosphorylation, and thereby activation, of AMPK by directly
binding to the g subunit of AMPK and changing the
conformation of the kinase, making it a better substrate for
the upstream kinase (Hawley et al., 2002) and a worse substrate
for the phosphatase (Davies et al., 1990). By controlling the
activity and expression of important rate-limiting enzymes of
carbohydrate, fat and protein metabolism, AMPK regulates the
cell energy status through conservation of ATP levels.
5-Aminoimidazole-4-carboxamide-1-h-d-ribofuranoside
(AICAR), an analog of adenosine, is widely used to activate
AMPK in vitro. After entering cells, it is phosphorylated to
form AICA ribotide (ZMP), an analog of AMP. ZMP, though
less effective than AMP, mimics all the activating effects of
AMP in the AMPK cascade (Corton et al., 1995). Thus,
AICAR provides a means of activating AMPK withoutaffecting AMP or ATP levels. In a previous study, AICAR
was shown to rapidly stimulate GVB in mouse oocytes
maintained in meiotic arrest with a variety of inhibitors
(Downs et al., 2002). AICAR was more potent in denuded
oocytes (DO) than cumulus cell-enclosed oocytes (CEO),
identifying the oocyte as the target of AICAR action. Meiotic
resumption was also induced by AMP in dbcAMP-arrested
oocytes. Therefore, these data were consistent with the
possibility that activation of AMPK provides a potent
meiosis-inducing signal.
In the present study, we determined if AMPK has a
causative role in GVB in mouse oocytes by modifying AMPK
activity and relating it to meiotic status. Using four different
strategies to expose oocytes to active AMPK and using two
putative inhibitors to block AMPK activity, we show that
stimulation of AMPK in prophase-I-arrested oocytes leads to
meiotic resumption and that preventing AMPK activation
abolishes the meiotic response.
Materials and methods
Oocyte isolation and culture conditions
C57BL/6JxSJL/J F1 mice, 19–23 days old, were used for all experiments.
Mice were primed with 5 IU equine choronic gonadotropin and killed 48 h later
by cervical dislocation. Ovaries were removed and placed in the culture
medium, and cumulus cell-enclosed oocytes (CEO) were obtained by
puncturing large antral follicles with sterile needles. Denuded oocytes were
prepared by repeated pipetting with a Pasteur pipette. Oocytes were cultured in
glass tubes for long-term culture (17–18 h) or in plastic tubes for short-term
culture (4 h). Tubes were gassed with a humidified mixture of 5% CO2, 5%
O2 and 90% N2 and placed in a water bath at 37-C for the duration of culture.
The culture medium used for most experiments was Eagle’s minimum essential
medium with Earle’s salts (GIBCO), supplemented with 0.23 mM pyruvate,
penicillin, streptomycin sulfate and 3 mg/ml crystallized lyophilized bovine
serum albumin (ICN ImmunoBiologicals, Lisle, IL) and buffered with 26 mM
bicarbonate. For oocyte microinjection, medium was buffered with 25 mM
HEPES, pH 7.2, with bicarbonate reduced to 6 mM.
Microinjection of active/dead AMPK
To test the effects of microinjected AMPK on oocyte maturation, denuded
oocytes were maintained in meiotic arrest with 300 AM dbcAMP and
microinjected with a preparation of either constitutively active AMPK
(T172D) or dead (inactive) kinase (D139A), each at a concentration of 7.5
mg/ml. Oocytes were placed into a micro-culture dish at room temperature, and
approximately 3–10 pl of solution containing active or inactivate kinase was
injected into the cytoplasm of germinal vesicle-stage oocytes using femtotip II
needles with an Eppendorf Transjector 5246 system (Eppendorf, Madsion, WI)
under a Nikon Diaphot 200 inverted microscope equipped with Nomarski
optics. Following microinjection, oocytes were transferred to 500 Al of
dbcAMP-containing medium under mineral oil and placed in a 37-C incubator
for 22 h. A positive control was included in which non-injected oocytes were
cultured in medium containing dbcAMP plus 250 AM AICAR. At the
conclusion of the incubation period, oocytes were assessed for GVB.
Construction and expression of GST-AMPK a1 catalytic domain
proteins (T172D, D139A)
Plasmid DNA encoding GST-tagged AMPK a1 catalytic domain has been
previously described (Scott et al., 2002). This DNA was used in site-directed
mutagenesis (QuickChange, Stratagene) to generate constitutively active
(T172D) and kinase dead (D139A) GST-tagged AMPK a1 catalytic domain
Fig. 1. Microinjection of constitutively active AMPK induces meiotic
resumption in dbcAMP-arrested oocytes. Oocytes were maintained in meiotic
arrest with 300 AMdbcAMP andmicroinjected with either a constitutively active
AMPK or a catalytically inactive (dead) AMPK preparation (injection volume
approximately 3–9 pl). Culture was continued for 20–21 h before assessing
GVB. The number of oocytes in each group is shown at the top of the bar.
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GGT GAATTT TTA AGA GAC AGC TGT GGC TCG CCC (sense) and GGG
CGA GCC ACA GCT GTC TCT TAA AAA TTC ACC (antisense), D139A
mutation ATG GTG GTC CAC AGA GCT TTG AAA CCT GAA AAC (sense)
and GTT TTC AGG TTT CAA AGC TCT TGT GAC CAC CAT (antisense).
The underlined bases indicate the sites on the codon where the mismatch was
placed. All proteins were expressed in E. coli (BL21) and purified on
glutathione sepharose as previously described (Scott et al., 2002).
Western blots
DO and oocyte – cumulus cell complexes (OCC) were washed in
phosphate-buffered saline (PBS, pH 7.4)/PVP (3 mg/ml) plus protease
inhibitors (Protease Inhibitors Cocktail Tablets, 1 mM Na orthovanadate, 2
Ag/ml pepstatin, 50 mM h-Glycerophospate) and then added to an equal
volume of 2 Laemmli’s buffer containing 20% h-mercaptoethanol. After
heating at 95-C for 5 min, samples were stored frozen at 80-C until used for
Western blotting. For Western analysis, proteins were electrophoresed on a 3–
8% Tris–Acetate mini Gel (Invitrogen) for 1 h at 150 V and then transferred to
nitrocellulose at 100 V for 1 h. To obtain the sharpest bands for active AMPK
(PT172) in Fig. 2B, samples were electrophoresed on a 4–12% Bis–Tris SDS
mini Gel (Invitrogen) for 50 min at 100 V and then in a semi-dry system
transferred to nitrocellulose at 400 mA for 2.5 h at 4-C. Blots were blocked
with 5% nonfat milk for 2 h at room temperature and then incubated with
primary antibodies (1:250) overnight at 4-C, washed in Tris-buffered saline
(TBS pH 7.4) 3 15 min, and incubated with HRP-conjugated IgG (1:2000) for
1 h at room temperature. Detection was performed with Supersignal Western
Pico Chemiluminescent Substrate (Pierce; Rockford, IL) and exposed on auto
radiographic films. Blots were stripped (7 Al/ml BME, 2% SDS, room
temperature 30 min) and reprobed with regular ACC antiserum (1:2000) as a
loading control. Bands were quantified by UVP BioImaging Systems (UVP,
Inc.; Upland, CA), and ratios of pACC/ACC were presented as the mean of two
determinations.
Anti-pACC was purchased from Upstate Biotechnology Inc. (Lake Placid,
NY); anti-ACC antibodies were generated in Dr. Hardie’s laboratory; anti-
PT172 antibody was obtained from Cell Signaling Technology (Beverly, MA).
AMPK assay
AMPK activity was measured as previously described (Downs et al., 2002;
Hardie et al., 2000a,b). Four hundred GV-stage oocytes from each treatment
group were collected and washed several times in immunoprecipitation (IP)
buffer and frozen at 80-C. IP buffer for oocytes contained: 50 mM Tris–HCl,
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 1 mM Na
orthovanodate, protease inhibitor cocktail tablet (Roche, Germany), Na
pyrophosphate (0.5834 g/250 ml) and 1 mM dithiothreitol.
DNA staining
After 17–18 h of culture, DO were fixed in 3% formaldehyde in PBS for
0.5–1 h. Oocytes were then transferred to a microscope slide and dried on a
warming tray. 10 Al glycerol:PBS (1:1) containing 1 Ag/ml Hoechst 3342
(Polysciences, Warrington, PA) was added, and a cover slide was immediately
placed on the oocytes and sealed with nail polish. Meiotic status was
determined using a Leitz Ortholux II fluorescent microscope.
AMP/ATP level measurement
Denuded oocytes were cultured for varying periods in organ culture dishes
containing 1 ml medium. After the designated culture times, individual oocytes
were assayed for AMP or ATP.
AMP was assayed as described in Chang et al. (2004). ATP was measured
as specified in Chi et al. (2002). Briefly, after different treatments, individual
oocytes were extracted by 0.5 Al 0.1 N NaOH at room temperature for 20 min,
0.5 Al of the extract was heated to 80-C for 20 min, and a 0.2 Al mixture of 0.2
N HCl and 0.1 M Tris–HCl (pH 6.8) was added. The NADP+ cycling reagent
was used for the ATP assay, containing 100 mM imidazole HCl (pH 7.0), 7.5mM a-ketoglutarate, 5 mM glucose 6-phosphate, 25 mM NH4Ac, 0.02% BSA,
100 AM ADP, 100 Ag/ml beef liver glutamate dehydrogenase and 10 Ag/ml
Leuconostoc mesenteroides glucose 6-phosphate dehydrogenase. The indicator
reaction for the NADP+ cycling step involves adding 10 Al of the reaction to 1
ml of the indicator, 6-phosphogluconate reagent, containing 50 mM imidazole
HAc (pH 7.0), 1 mM EDTA, 30 mM NH4Ac, 5 mM MgCl2, 100 AM NADP+
and 2 Ag/ml yeast 6-phosphogluconate dehydrogenase.
Statistical analysis
Oocyte maturation experiments were repeated at least 3 times with at least
25 oocytes per experiment. Data are reported as mean percentage GVB T SEM.
Maturation frequencies were subjected to arcsin transformation and analyzed
statistically by ANOVA followed by Duncan’s multiple range test. For all
statistical analyses, a P value less than 0.05 was considered significant.
Results
Microinjection of active AMPK induces oocyte maturation
To directly determine if active AMPK could stimulate
meiotic resumption, bacterially expressed constitutively active
(T172D) AMPK was injected into meiotically arrested
oocytes. Denuded oocytes (DO) maintained in meiotic arrest
with dbcAMP were microinjected with either a constitutively
active AMPK or a catalytically inactive (dead) AMPK
preparation. DO cultured with AICAR served as a positive
control. The results of two experiments are shown in Fig. 1.
After 21–22 h of culture, AICAR stimulated most of the
arrested oocytes to resume maturation (94–100% GVB
compared to 0–2% of control oocytes), indicating the system
is responsive to an appropriate meiosis-inducing stimulus.
About 20% of the oocytes receiving active AMPK were
stimulated to undergo maturation. Although this was a smaller
effect than that of AICAR, the catalytically inactive kinase had
no effect.
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AICAR, an AMPK activator, is a very potent inducer of
oocyte maturation and stimulates AMPK activity in mouse
oocytes (Downs et al., 2002). To assess the activation state of
AMPK on Western blots, two different antibodies were used,
anti-PT172 and anti-phospho-acetyl CoA carboxylase (Ser-79-
pACC). Anti-PT172 antibody recognizes phosphorylated Thr-
172 on the catalytic subunit and correlates with AMPK
activity. ACC, an enzyme involved in fatty acid metabolism,
is a major substrate of AMPK (Davies et al., 1992), and its
phosphorylation state on Ser-79 is commonly used as an
indirect assay for AMPK activity. Extracts were prepared
from 230 oocyte–cumulus cell complexes (OCC) cultured for
4 h in 300 AM dbcAMP plus or minus 1 mM AICAR.
Phosphorylation of Thr-172 was evident in freshly isolated
complexes, but this decreased in intensity after culture, while
addition of AICAR to the culture medium restored the high
level of AMPK activity (Fig. 2A). A similar pattern was seen
in the pACC blots.Fig. 2. Western analysis of phosphorylation of AMPK (at pT172) and
phosphorylation of ACC (pACC) in OCC and DO. (A) Extracts were
prepared from freshly isolated OCC or OCC cultured 4 h in 300 AM
dbcAMP with (AICAR) or without (Con) 1 mM AICAR (230 OCC per
lane). Blots were stripped and reprobed with anti-ACC antibody as a loading
control. (B) AMPK and pACC levels in freshly isolated DO or DO cultured
2 h in 300 AM dbcAMP with (AICAR) or without (Con) 500 AM AICAR.
Only germinal vesicle (GV)-stage oocytes were collected and assayed (500
oocytes per lane). (C) DO were freshly isolated or cultured in 300 AM
dbcAMP with (+) or without () AICAR (250 AM) for 1, 2, or 4 h (235
oocytes per lane). All oocytes were at the GV stage, except for the 4 h AICAR-
treated group, which contained only germinal vesicle breakdown (GVB)-stage
oocytes.The experiments were repeated in DO. DO were cultured in
300 AM dbcAMP plus or minus AICAR for 2 h, and only GV-
stage oocytes were collected for analysis. For the above blot,
extract from OCC was electrophoresed on a 3–8% Tris–
Acetate gel, which produces distinct bands for pACC but more
blurred bands for PT172. Initial attempts at using this gel for
detection of PT172 in oocyte extracts proved unsuccessful;
consequently, we carried out electrophoresis using a 4–12%
Bis–Tris gel. Under these conditions, phosphorylation of Thr-
172 on AMPK was detected in freshly isolated oocytes that
decreased after 2 h of culture in dbcAMP alone but was
increased by AICAR treatment (Fig. 2B). Ser-79 phosphory-
lation on ACC showed the same pattern, but the bands were
less distinct. That the phosphorylation of Ser-79 on ACC
parallels that of Thr-172 on ACC confirms the usefulness of the
anti-pACC antibody as a marker of AMPK activity in mouse
oocytes. The elevated phosphorylation of AMPK in the
AICAR-treated GV-stage DO suggests that AMPK is activated
prior to oocyte meiotic resumption, which supports the idea
that AMPK triggers oocyte maturation.
Using the anti-pACC antibody, a more detailed time course of
AMPK activation by AICAR in DO was determined. DO were
cultured in 300 AM dbcAMP with or without AICAR (250 AM)
for 1, 2 or 4 h before probing extracts for AMPK activity with
anti-pACC antibody. All oocytes used for analysis were at the
germinal vesicle (GV) stage, except for the 4 h AICAR-treated
group, which contained only germinal vesicle breakdown
(GVB)-stage oocytes. For this and all subsequent pACCWestern
blotting, we utilized 3–8% Tris–Acetate gels. Results of the
time course experiment show that AMPK is activated within 1
h of culture (Fig. 2C), well before the initiation of meiotic
induction, which is not manifested until after 2 h of culture under
these conditions (Downs et al., 2002).
To directly measure AMPK activity in AICAR-treated GV-
stage oocytes, SAMS peptide phosphorylation assays were
performed. SAMS peptide is a peptide sequence based on the
unique phosphorylation site (Ser-79) of ACC for AMPK and is
a specific substrate for the kinase (Davies et al., 1989). Extracts
were assayed from GV-stage fresh DO or from GV-stage DO
cultured for 2 h in dbcAMP-containing medium in the presence
or absence of AICAR. Fresh oocytes contained a high level of
AMPK activity that was reduced by 86% after 2 h of culture
under meiosis-arresting conditions (Fig. 3). In agreement with
the results of Western blotting, AICAR increased the AMPK
activity 3.4-fold (Fig. 3), thereby confirming that an increase in
AMPK precedes GVB.
AMPK inhibitors block AMPK activation and AICAR-induced
oocyte maturation
Compound C, a potent small-molecule AMPK inhibitor
(Zhou et al., 2001), was tested on AICAR-induced oocyte
maturation. DO were preincubated with increasing concentra-
tions of compound C in dbcAMP-containing medium for 0.5
h before addition of 250 AM AICAR, and cultures were
continued for 4 h before GVB assessment. A parallel group of
DO was cultured 4.5 h in dbcAMP-supplemented medium
Fig. 4. Effects of compound C on AICAR-induced meiotic maturation and
ACC phosphorylation. (A) DO were preincubated 0.5 h in medium containing
300 Am dbcAMP with or without increasing concentrations of compound C.
AICAR was then added to some of the tubes, and cultures were continued for 4
h before assessment of GVB. (B) Western analysis of pACC in extracts of GV-
stage DO (250 oocytes per lane). Extracts were prepared from GV-stage DO
cultured 2 h in medium containing 300 AM dbcAMP, dbcAMP plus AICAR
(500 AM) or dbcAMP plus both AICAR and compound C (5 AM). The mean
pACC/ACC ratio of two blots is shown in the corresponding graph, normalized
to the dbcAMP alone control group.
Fig. 3. Effect of AICAR on AMPK activity in GV-stage oocytes. AMPK
activity was analyzed in extracts from freshly isolated oocytes or from GV-
stage oocytes after 2 h culture in 300 AM dbcAMP alone (Control) or dbcAMP
plus 500 AM AICAR (+AICAR). A different letter denotes a significant
difference.
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without added AICAR. In the absence of AICAR, 34% of
the control oocytes resumed maturation, and compound C
exerted a modest inhibitory effect (Fig. 4A). AICAR treatment
increased the maturation percentage to 83%, and this
stimulation was dose-dependently eliminated by compound
C. Inhibition was reversible as it was eliminated by washing
out compound C and further culture in dbcAMP-free medium
(data not shown).
To assess the effect of compound C on AMPK activity in
these oocytes, pACC levels were determined in GV-stage
oocytes by Western blot analysis. After 2 h of culture, very
little phosphorylation of ACC was detected in oocytes cultured
in dbcAMP alone, but this was increased by AICAR treatment.
Exposure of AICAR-treated oocytes to compound C signifi-
cantly reduced phosphorylation of pACC, indicating suppres-
sion of AMPK activity within oocytes (Fig. 4B).
To rule out the possibility of a general toxic effect,
compound C was tested on okadaic acid (OA)-induced
oocyte maturation. DO were pre-treated with dbcAMP plus
increasing concentrations of compound C for 0.5 h before
adding OA, and GVB was assessed after 4 additional hours
of culture. Compound C had no inhibitory effect on OA-
induced oocyte maturation even at a concentration 10-fold
higher than that which effectively blocked AICAR-induced
maturation (Fig. 5A). The kinetics of OA-stimulated GVB
was only slightly delayed by 5 AM compound C (data not
shown). Extracts from GV-stage oocytes after 1.5 h treatment
with 1 AM OA revealed only a modest activation of AMPK
when compared to AICAR-treated oocytes (Fig. 5B). These
results show that compound C is not a non-specific
inhibitor of maturation and indicate that AMPK activation
is not the principal means by which OA stimulates meiotic
resumption.
AICAR is transported into cells via the adenosine transport
system and is then phosphorylated by adenosine kinase to form
the AMP analog, ZMP (Corton et al., 1995; Gadalla et al.,
2004). To discount the possibility that compound C blocksAMPK activation by inhibition of AICAR transport into the
oocytes or its conversion to ZMP, we tested the effect of
compound C on: (1) the uptake of radiolabeled adenosine by
mouse oocytes and (2) adenosine-stimulated ATP production in
oocytes. To measure possible effects on AICAR uptake, DO
were cultured 30 min in control medium or medium containing
2 mM uridine or increasing concentrations of compound C.
Tritiated adenosine was then added, and cultures were
continued for 3 h. Uridine served as a positive control for
adenosine transport inhibition (Downs, 1999). Fig. 6 shows the
mean of two experiments. Compound C did not affect the
uptake of adenosine at concentrations that completely sup-
pressed AICAR-induced maturation, while uridine totally
eliminated uptake (Fig. 6A). To test compound C for an effect
on adenosine kinase, DO were cultured for 3 h in control
Fig. 5. Effects of compound C on okadaic-acid (OA)-induced meiotic
resumption and ACC phosphorylation. (A) DO were preincubated with
increasing concentrations of compound C for 0.5 h before adding 1 AM OA
in 300 AM dbcAMP-containing medium. GVB percentage was assessed after 4
h of culture. (B) Western analysis of pACC levels in OA-treated GV-stage
oocytes (250 oocytes per lane). DO were treated in 300 AM dbcAMP
containing medium with 1 AM OA or 500 AM AICAR for 1.5 h. The mean
pACC/ACC ratio of two blots is shown in the corresponding graph, normalized
to the dbcAMP alone control group.
Fig. 6. Effects of compound C on adenosine uptake and adenosine
phosphorylation in DO. (A) DO were cultured 30 min in control medium o
medium containing 2 mM uridine or increasing concentrations of compound
before the addition of tritiated adenosine and the continuation of culture for 3 h
Groups of 25 oocytes were analyzed for radioactivity by scintillation
spectroscopy (mean T SEM of three experiments). (B) DO were cultured 3
h in control medium or medium containing 250 AM adenosine or adenosine
plus 5 AM compound C. Individual oocytes were then analyzed for ATP. The
number of oocytes assayed is given below each bar. An asterisk denotes a
significant difference from the control group.
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presence or absence of compound C, and individual oocytes
were then analyzed for ATP. As shown in Fig. 6B, adenosine
stimulated an increase in ATP levels that was not affected by
the presence of compound C. These data demonstrate that the
ability of the oocyte to take up and convert AICAR to ZMP
was not compromised by compound C.
Adenine 9-h-d-arabinofuranoside (araA) is the precursor
of araATP, a competitive inhibitor of AMPK (Henin et al.,
1996). We tested this inhibitor on AICAR-induced matura-
tion to determine if it could duplicate the inhibitory action
of compound C. Oocytes were pretreated with dbcAMP plus
increasing concentrations of araA for 0.5 h before adding
250 AM AICAR, and GVB percentages were determined
after 4 additional hours of culture. AICAR increased the
maturation percentage from 20% to 80%, and this was
blocked by araA in a dose-dependent fashion (Fig. 7A).
Western analysis demonstrated an increased phosphorylation
of ACC in response to AICAR that was suppressed by araA
(Fig. 7B).AICAR and its metabolites may have effects unrelated to
AMPK activation (Kemp et al., 1999), and it was therefore
important to consider alternative methods to stimulate the
activity of the kinase and relate the activity to meiotic status. To
accomplish this end, we utilized two additional strategies, (1)
manipulation of adenosine metabolism and (2) treatment of
oocytes with the anti-diabetic agent rosiglitazone.
DCF plus adenosine induces oocyte maturation and AMPK
activation
Adenosine, a component of follicular fluid, exerts a meiosis-
arresting action on oocytes (Eppig et al., 1985; Miller and
Behrman, 1986; Salustri et al., 1988; Downs, 1999). This
nucleoside has two main metabolic routes within cells—
phosphorylation by adenosine kinase to generate AMP andr
.
Fig. 7. Effects of araA on AICAR-induced oocyte maturation and ACC
phosphorylation. (A) DO were pretreated 0.5 h in 300 AM dbcAMP-
supplemented medium with increasing doses of araA; 250 AM AICAR was
then added, and cultures were continued for 4 h before assessment of GVB. A
different letter denotes a significant difference. (B) Western analysis of pACC
levels in araA and AICAR-treated GV-stage oocytes (250 oocytes per lane).
DO were preincubated with 1 mM araA for 0.5 h in 300 AM dbcAMP before
adding 500 AM AICAR, and cultures were continued for 2 h. The mean pACC/
ACC ratio of two blots is shown in the corresponding graph, normalized to the
dbcAMP control group.
Fig. 8. DCF reversal of the inhibitory effect of adenosine on oocyte meiotic
resumption. (A) DO were cultured in 150 AM dbcAMP or adenosine plus 250
AM DCF, with increasing concentrations of adenosine. After 17–18 h culture,
oocytes were fixed and stained with Hoechst, and GVB was assessed under a
fluorescent microscope. Groups with at least one identical letter are not
significantly different. (B) Kinetics of DCF effects on adenosine-treated oocyte
maturation. DO were cultured in 150 AM dbcAMP, dbcAMP plus 250 AM
adenosine or dbcAMP plus adenosine and 250 AM DCF. Meiotic resumption
was determined at the indicated times. (C) Western analysis of pACC in DCF-
treated GV-stage oocytes (250 oocytes per lane). DO were cultured 6 h in 150
AM dbcAMP, dbcAMP plus 250 AM adenosine or dbcAMP plus adenosine and
250 AM DCF.
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Deoxycoformycin (DCF), an adenosine deaminase inhibitor,
has no effect on oocyte maturation on its own but can reverse
the inhibitory effect of adenosine in CEO (Downs, 1999;
Downs et al., 2002). This led to the idea that blocking
deamination of adenosine might divert increased adenosine
through adenosine kinase, causing an accumulation of AMP,
activation of AMPK and meiotic induction.
We first tested the effects of DCF on adenosine-mediated
meiotic arrest. DO were cultured for 17–18 h in medium
containing 150 AM dbcAMP plus increasing concentrations
of adenosine in the absence or presence of 250 AM DCF.
This lower concentration of dbcAMP was used to achieve a
suboptimal level of inhibition that would then be augmented
by the addition of adenosine (cf. Downs, 1999), because
adenosine alone has a very limited inhibitory effect. As
shown in Fig. 8, adenosine dose-dependently suppressed
oocyte maturation, while at each concentration DCF com-pletely reversed this effect. A time course experiment
showed that the meiotic induction brought about by DCF
treatment was slow: a small increase in maturation was
evident after 6 h of culture, with complete reversal achieved
by 18 h (Fig. 8B).
Western blot analysis was next performed to assess the
phosphorylation of ACC in oocytes treated with or without
DCF, in the presence of adenosine. GV-stage oocytes were
J. Chen et al. / Developmental Biology 291 (2006) 227–238234collected after 6 h of treatment with adenosine alone or with
adenosine plus DCF. Little phosphorylation of ACC was
observed in the adenosine alone group, but significant
phosphorylation was stimulated upon addition of DCF
(Fig. 8C).
To further clarify the effect of DCF on adenosine-treated
oocytes, experiments were performed to measure oocyte AMP
and ATP levels. In individual oocytes, ATP was measured in
freshly isolated oocytes or oocytes cultured 5 h in control
inhibitor-free medium or in medium containing adenosine
alone, DCF alone or adenosine plus DCF. Fresh oocytes
contained 3.55 mmol ATP per kg wet wt of oocyte, and this
decreased to 2.5 mmol per kg after culture in control medium
for 5 h (Fig. 9A). Adenosine or DCF alone had a modestFig. 9. AMP/ATP levels in DCF- and adenosine-treated oocytes. (A) ATP was
measured in fresh DO or DO cultured 3 h in control medium or medium
containing 250 AM adenosine, 250 AM DCF or adenosine plus DCF. The
number of oocytes assayed in each group is given below each bar. Groups with
at least one identical letter are not significantly different. (B) AMP was
measured in fresh oocytes or in oocytes cultured 3 or 5 h in control medium or
in medium containing 250 AM adenosine, 250 AM DCF or dbcAMP plus DCF.
The number of oocytes assayed per treatment group ranged from 31 to 40.
Fig. 10. Effects of rosiglitazone on meiotic resumption and ACC phosphor
ylation. (A) DO or CEO were cultured 17–18 h in 4 mM HX with increasing
concentrations of rosiglitazone and then assessed for GVB. There was no
significant difference between any of the CEO groups. Within the DO groups, a
different letter denotes a significant difference. (B) Western analysis of GV
stage DO after 2 h of treatment with (Ros) or without (Con) 100 AM
rosiglitazone (500 oocytes per lane). 500 AM AICAR-treated oocytes were
shown as a positive control.-
-stimulatory effect on ATP levels, but the combination of
adenosine plus DCF profoundly increased ATP, even well
above the levels observed in fresh oocytes. These results
demonstrate that DCF treatment elicits a significant shift in
adenosine metabolism towards phosphorylation.
AMP levels were next examined under the same culture
conditions, with measurements taken at 0, 3 and 5 h. These
results are shown in Fig. 9B. Fresh oocytes contained 1.25
mmol AMP per kg wet wt of oocyte. In control medium or in
medium containing adenosine or DCF alone, AMP remained
unchanged or decreased after 3 and 5 h of culture. However, in
the adenosine plus DCF group, AMP was significantly
increased by 5 h. These results are consistent with AMP-
induced activation of AMPK as the mechanism for the DCF-
mediated reversal of adenosine-maintained meiotic arrest.
Rosiglitazone-induced meiotic resumption and AMPK
activation
Rosiglitazone is an anti-diabetic agent that has recently
been shown to activate AMPK by increasing the cellular
AMP/ATP ratio (Fryer et al., 2002a). We therefore tested the
effect of rosiglitazone on meiotic maturation and AMPK
activation. Because preliminary attempts to treat dbcAMP-
arrested oocytes with rosiglitazone produced inconsistent
results on oocyte maturation, we report the actions of the
drug on oocytes maintained in meiotic arrest with hypoxan-
thine. DO or CEO were cultured for 17–18 h in 4 mM
hypoxanthine plus increasing concentrations of rosiglitazone
before assessment of GVB. Although it did not affect oocyte
maturation in CEO, rosiglitazone at 100 AM increased the
frequency of meiotic resumption in DO from 61% to 79%
(Fig. 10A). Higher concentrations of rosiglitazone were toxic
to oocytes, increasing the level of cell death (data not shown)
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revealed increased phosphorylation of ACC in GV-stage
oocytes cultured for 2 h in 300 AM dbcAMP plus rosiglitazone
compared to oocytes cultured in dbcAMP alone, with
phosphorylation of ACC being greatest in the AICAR-treated
oocytes (Fig. 10A).
AMPK and spontaneous maturation
Two types of experiments were carried out to test for
possible AMPK involvement in spontaneous maturation. In
the first experiment, DO were held in meiotic arrest for 0.5
h with 300 AM dbcAMP in the presence or absence of 5 AM
compound C. Oocytes were then washed free of dbcAMP, and
cultures were continued for varying periods of time. As shown
in Fig. 11A, compound C produced a significant delay in
oocyte maturation. To determine if AMPK is activated in
spontaneously maturing oocytes prior to GVB, DO were
maintained in meiotic arrest with dbcAMP for 2 h, after which
they were split into two groups, one remaining in dbcAMP for
0.5 h and the other washed free of dbcAMP and cultured for
0.5 h in control inhibitor-free medium. The 2-h preincubation
assured a drop in phosphorylated ACC from fresh levels
before the release from dbcAMP arrest. Extracts from GV-
stage oocytes were then processed for pACC Western analysis.
When oocytes were maintained in meiotic arrest for 2.5 h,
very little phosphorylation of ACC was detected, whereas
oocytes cultured in the absence of dbcAMP for the last 0.5
h exhibited a prominent pACC band, indicating active AMPK
(Fig. 11B).Fig. 11. AMPK involvement in spontaneous maturation. (A) DO were cultured
0.5 h in medium containing 300 AM dbcAMP with or without 5 AM compound
C. They were then washed free of dbcAMP and cultured for varying periods up
to 3 h in the presence or absence of 5 AM compound C before assessment of
GVB. (B) Western analysis of GV-stage DO after 2 h preincubation in 300 Am
dbcAMP followed by either 0.5 h in dbcAMP (+dbc) or 0.5 h in inhibitor-free
control medium (dbc) (250 oocytes per lane).Discussion
In the present study, we present results that strongly support
a causal role for AMPK in meiotic maturation. The new
evidence may be summarized as follows:
(1) Microinjection of constitutively active, but not catalyti-
cally inactive, kinase into dbcAMP-arrested oocytes
stimulated GVB.
(2) Both Western blot analysis and kinase assays indicated
that AMPK activity was increased in AICAR-treated
oocytes prior to meiotic resumption.
(3) Compound C and araA, two pharmacological inhibitors
of AMPK, blocked AICAR-induced oocyte meiotic
resumption and decreased the activity of AMPK in
AICAR-treated, GV-stage oocytes, as judged by phos-
phorylation of ACC.
(4) Activation of AMPK by two additional means, i.e.,
rosiglitazone or adenosine plus DCF, also triggered
meiotic maturation.
(5) AMPK activity increased prior to GVB in spontaneously
maturing oocytes; moreover, compound C transiently
blocked spontaneous maturation.
Eliciting GVB by microinjection of active, but not inactive,
AMPK catalytic subunit demonstrates that AMPK can directly
stimulate meiotic resumption. In these experiments, we used a
constitutively active (T172D) mutant that would not be
sensitive to the protein phosphatases that would be present in
the oocytes. Microinjection of active kinase stimulated an
increase in GVB of about 20%, while the meiotic induction
achieved by AICAR was much higher. There could be a
number of reasons why stimulation of GVB by active kinase
may be limited compared with the effects of AICAR. For
example, only the kinase domain of the a1 subunit was
injected. The a1 and a2 isoforms appear to have rather similar
specificity in solution (Woods et al., 1996), but the kinase
domain represents only about 25% of the total sequence of an
ahg hetertrimer, and the a1 kinase domain may lack targeting
sequences that direct the kinase to the substrate required for the
effect on oocyte maturation. Despite the limited size of the
effect, the ability of constitutively active AMPK to stimulate
meiotic resumption strongly supports a positive role for the
kinase in meiosis.
In a previous study, we showed that AICAR, known to be a
potent activator of AMPK in somatic cells, stimulated meiotic
resumption and AMPK activation in mouse oocytes (Downs et
al., 2002). In the present study, we provide evidence that the
ability of AICAR to stimulate maturation is due to AMPK
activation. Using both anti-PT172 and anti-pACC antibodies as
probes, Western blot analysis revealed that AMPK was
activated at the GV stage by AICAR, and this was confirmed
by AMPK kinase assays using the SAMS peptide as substrate.
While GVB is initiated by AICAR after more than 2 h of
culture (Downs et al., 2002), AMPK is already activated within
1 h. Thus, AMPK activation precedes GVB, a finding
consistent with its function as a meiotic inducer.
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meiotic resumption was provided by experiments with inhibi-
tors. Compound C was the first potent and selective inhibitor of
AMPK to be described (Zhou et al., 2001), while araA, a
precursor of araATP, has also been shown to competitively
suppress AMPK activity (Henin et al., 1996). Both inhibitors
blocked AICAR-induced maturation in a dose-dependent
fashion and prevented AMPK activation as assessed by
phosphorylation of ACC. While the specificity of these
inhibitors for AMPK may not be absolute, their ability to block
both AICAR-induced maturation and AMPK activation, despite
the fact that they inhibit AMPK via different mechanisms, lends
credence to the idea that AMPK is a meiotic inducer.
One point of concern for compound C was the possibility
that it might act by preventing AICAR uptake and accumula-
tion of ZMP (Fryer et al., 2002a,b). Since AICAR is an
adenosine analog, we tested the effects of compound C on
adenosine uptake and its metabolism to ATP. Neither uptake of
adenosine nor its stimulation of ATP production was adversely
affected by compound C, thereby discounting a negative
influence in ZMP generation. It should also be noted that
compound C completely blocked meiotic induction by three
different stresses, none of which involved metabolic processing
of exogenous nucleoside (LaRosa and Downs, in press).
To determine if compound C exerts a non-specific inhibitory
influence on meiosis, we tested its effect on okadaic acid (OA)-
induced maturation. OA is an inhibitor of protein phosphatase 1
and 2A that has been shown to stimulate oocyte maturation in
many species (Alexandre et al., 1991; Gavin et al., 1991;
Schwartz and Schultz, 1991). Recent work shows that protein
phosphatase 1 is the OA-sensitive protein phosphatase impor-
tant in the regulation of the acquisition of meiotic competence,
nuclear events during meiotic arrest and GVB in mouse oocytes
(Wang et al., 2004). OA is involved in regulation of protein
kinase B (PKB) activity, which plays a role in CDK1 activation
and meiotic resumption in mouse oocytes (Kalous et al., 1999).
In mouse oocytes, OA is a potent inducer of meiosis, stimulating
GVB within 1.5 h in dbcAMP-arrested oocytes, with induction
completed by 3 h (LaRosa and Downs, 2005). In this study,
compound C had no inhibitory effect on OA-induced maturation
during overnight culture, and only marginally attenuated the
kinetics of OA-induced maturation, thereby demonstrating
specificity in the inhibitory actions of the drug. Moreover,
Western blot analysis revealed that, although GV-stage oocytes
after 1.5 h of OA treatment contained relatively higher amounts
of phosphorylated ACC compared to control oocytes cultured in
dbcAMP alone, these levels were still lower than in AICAR-
treated oocytes. These results provide evidence that OA
treatment may lead to some degree of AMPK activation but
that such activation is not necessary for OA-induced maturation.
Despite AICAR serving as an effective stimulator of both
AMPK activation and meiotic maturation, it remained possible
that it could influence meiosis by means unrelated to AMPK
activation (Kemp et al., 1999). It was therefore important to
employ additional strategies for generating active kinase and
relating that activity to meiotic status. To achieve this, we
utilized two different treatments: (1) adenosine plus DCF and(2) rosiglitazone. DCF, a potent adenosine deaminase inhibitor,
reversed the inhibitory effect of adenosine on oocyte maturation
in CEO (Downs, 1999, 2002). We hypothesized that, by
blocking adenosine deaminase, adenosine metabolism was
diverted towards phosphorylation, resulting in AMP accumula-
tion, activation of AMPK and meiotic induction (Downs et al.,
2002). In the present study, we confirmed that there was a
stimulatory action of DCF on oocyte maturation and showed
that AMPK activity was, indeed, high prior to GVB. It was also
shown that DCF caused a diversion of adenosine towards the
phosphorylation pathway and a subsequent accumulation of
adenyl nucleotides. A buildup of oocyte AMP in the presence of
DCF was consistent with activation of AMPK and stimulation
of GVB. Interestingly, increases in both AMP and ATP were
observed in oocytes treated with adenosine and DCF. However,
as the affinity of the CBS domains on the g subunit for AMP is
higher than that for ATP (Scott et al., 2004), a small increase in
AMP should displace the ATP and increase the kinase activity.
We propose that the elevated AMP in oocytes is sufficient to
overcome the inhibitory effect of ATP on AMPK. Whether
alterations in oocyte AMP levels normally contribute to the
signal triggering meiotic resumption in vivo remains to be
determined.
We also tested the effect of the anti-diabetic thiazolidine-
dione drug rosiglitazone on oocyte maturation and AMPK
activation. This drug is an inhibitor of complex I of the
respiratory chain (Brunmair et al., 2004) and has been reported
to increase the AMP/ATP ratio with concomitant activation of
AMPK in a muscle cell line (Fryer et al., 2002a). Rosiglitazone
produced a small, but significant, increase in GVB in HX-
arrested DO, whereas it had no effect on meiotic induction in
CEO. The poor potency of rosiglitazone in meiotic induction
when compared to AICAR may be due to a weaker stimulation
of AMPK in mouse oocytes since GV-stage oocytes after 2 h of
treatment with rosiglitazone exhibited less intense phosphory-
lation of ACC than AICAR-treated oocytes. It should also be
noted that rosiglitazone at high concentrations is toxic to
oocytes. We suspect that this may be due to a reduction of ATP
concentrations below the threshold required to maintain oocyte
viability. Thus, there appears to be a narrow window of
rosiglitazone concentrations in which a small drop in ATP leads
to a weak activation of AMPK and a small effect on GVB but
that at higher concentrations any effect on meiotic resumption
is prevented by loss of viability.
Surprisingly, freshly isolated DO or OCC contained a high
level of phosphorylation of AMPK on Thr-172 and ACC on
Ser-79, indicating a high AMPK activity, and this was
confirmed by directly assaying oocyte extracts for AMPK
activity. However, this activity was greatly reduced within 1 h of
culture. AMPK is a stress-activated enzyme, and even gentle
physical manipulation can stimulate the kinase (Hardie et al.,
2000a,b). It therefore seems likely that the process of oocyte
isolation, involving ovary manipulation, piercing follicles with
needles, oocyte denudation and pipetting could contribute to the
high level of active AMPK in fresh oocytes. Yet, we cannot
discount the possibility that oocyte AMPK activity is high
at the time of isolation and that AICAR and the other meiosis-
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active kinase. Work is in progress to address this issue.
Two lines of evidence suggest that AMPK is involved also
in spontaneous maturation. First, compound C suppressed
spontaneous GVB at a concentration that was also effective on
meiotic induction; second, AMPK activity increased prior to
GVB in spontaneously maturing DO, as indicated by pACC
Western analysis. While these results support the participation
of AMPK, they do not establish whether AMPK activity is
essential for spontaneous maturation, particularly since the
arrest by compound C was transient.
The primary purpose of the present study was to establish
whether AMPK can stimulate meiotic resumption in mouse
oocytes. Although the methods employed to activate AMPK
may not have mimicked signals occurring in vivo, the results
nevertheless provide compelling evidence that AMPK is a
potent inducer of maturation. Current research is aimed at
determining what physiological role, if any, AMPK plays in the
control of oocyte maturation. Although the data indicate
involvement in both spontaneous maturation and meiotic
induction, the necessity for AMPK participation in meiotic
regulation remains to be demonstrated.
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